We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
BioVersys and SARomics Biostructures to Collaborate
News

BioVersys and SARomics Biostructures to Collaborate

BioVersys and SARomics Biostructures to Collaborate
News

BioVersys and SARomics Biostructures to Collaborate

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "BioVersys and SARomics Biostructures to Collaborate"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

BioVersys and SARomics Biostructures announced today that they will collaborate and bring
together their complementary expertise to tackle antimicrobial resistance in an international project supported by the European initiative EUROSTARS.


Antimicrobial resistance represents a major threat to public health worldwide and is far from being adequately addressed today, as evidenced by the low number of new products in clinical development. The SARTRIC project addresses this deficiency by restoring antibiotic activity by blocking the transcriptional activation of resistance genes with small molecules and thus restoring the efficacy of already marketed drugs. The two SME (small/medium enterprise) partners BioVersys AG (Basel, Switzerland) and SARomics Biostructures AB (Lund, Sweden) will combine their highly complementary technology modules, expertise and resources to drive the drug development process of initial hit molecules towards fully characterized lead molecules that qualify for preclinical testing. Part of the project will be financed by a Eurostars grant.


“It is a great pleasure to see the synergies between our two companies bearing fruit in an international collaboration with the support and funding of EUROSTARS.” explained Marcel Tigges, CSO at BioVersys.


“We are excited to collaborate with BioVersys on this potentially game-changing
approach that addresses a high unmet medical need.” says Dr. Björn Walse, CEO at
SARomics Biostructures.

Advertisement